Solving Slowing Progressive Renal Disease
|
|
- Jeffery Garrett
- 5 years ago
- Views:
Transcription
1 Focus on CME at Memorial University of Newfoundland Solving Slowing Progressive Risk factors and treatment strategies for patients with kidney and cardiovascular disease overlap. Thus, evaluating renal function in patients with diabetes, hypertension and cardiovascular disease is essential. By Brendan Barrett, MB, MSc, FRCPI, FRCPC The need to treat advanced renal disease is becoming more common and poses a significant burden on patients, families and the healthcare system. National registry data show the number of new dialysis patients in Canada increased by an average of 7% per year between 1981 and Dr. Barrett is associate professor, division of nephrology and clinical epidemiology unit, Memorial University of Newfoundland, St. John s, Newfoundland Over 12,000 Canadians were on dialysis by the end of 1998, and there may be as many as 20,000 such patients by The financial cost of caring for these patients is very high, with direct annual health-care costs ranging from about $32,570 for those on home hemodialysis, to $88,585 for those on hospital-based hemodialysis. Transplantation is a medically and economically superior treatment, but a shortage of organs and strict medical suitability criteria mean that many patients will be dependent on dialysis. The vast majority of patients reach end-stage renal disease (ESRD) as a result of chronic progressive kidney diseases. National registry data suggest diabetic nephropathy, hypertension/vascular diseases and glomerulonephritis are the The Canadian Journal of CME / April
2 The best clinical markers of significant renal disease are abnormal protein excretion and a falling glomerular filtration rate, as reflected by increased serum creatinine. leading causes of ESRD in Canadians. It is possible to recognize these chronic renal diseases before they become advanced, and available therapies can significantly slow the progressive loss of renal function they may cause. However, early renal disease is generally asymptomatic and, therefore, recognition requires a pro-active approach. Several things should happen once a patient is identified as having chronic renal disease. Where possible, the cause of the condition should be determined. Serial measurement of renal function is needed to determine how quickly the renal failure is progressing. The extent of co-morbidities, especially the commonly associated vascular diseases, must be assessed. Then, a comprehensive management plan is required to slow the decline in renal function, treat or prevent the complications of renal failure, and minimize the impact of comorbid illness. Interventions to prevent progressive loss of renal function and cardiovascular complications fortunately overlap. Regular physician input is important for these interventions to be effective. 126 The Canadian Journal of CME / April 2001
3 Males: Cockroft-Gault formula age (years) X body weight (kg) serum creatinine (µmol/l) X 0.8 Females: age (years) X body weight (kg) serum creatinine (µmol/l) Figure 1. Cockroft-Gault formula for estimation of creatinine clearance in mls/min from serum creatinine. Identifying Chronic A population-based study from Framingham found the prevalence of elevated creatinine levels to be over 8%; prevalence in the elderly was up to 20%. Those with hypertension, diabetes or on treatment for cardiac disease were more likely to have renal impairment. Based on these types of data, it is recommended that serum creatinine should be periodically checked in all diabetics, hypertensive patients and in those with atherosclerotic vascular disease. 1 Unexplained anemia, abnormal urinalysis or a family history of renal disease should also prompt a check of serum creatinine. 1 Pathologic renal damage can precede renal function decline by quite some time. The best clinical markers of significant renal disease are abnormal protein excretion and a falling glomerular filtration rate (GFR), as reflected by increased serum creatinine. Microalbuminuria (urinary albumin excretion between 30 mg/day and 300 mg/day) is seen at an early stage of diabetic nephropathy. Current guidelines recommend screening all diabetics for microalbuminuria if they do not already have proteinuria on regular dipstick testing. 2 This can be done by timed (e.g., 24-hour) urine collections or urine sampling for albumin-to-creatinine ratio. 2 Microalbuminuria is not specific to diabetic renal disease. Proteinuria also is seen with glomerular and hypertensive/vascular renal disorders. Heavy proteinuria of over 3 g/day (nephrotic range) is mostly seen with glomerular diseases either limited to the kidney or secondary to systemic disease, including diabetes. Microalbuminuria, or heavier proteinuria, is associated with a worse renal and cardiovascular prognosis. Proteinuria should be sought in populations at higher risk for renal disease, such as those with hypertension/vascular diseases, edema or a family history of renal disorders. Screening for proteinuria is not warranted in the general population. As mentioned above, it also is worthwhile to check serum creatinine in people at risk for renal disease. This includes those found to have proteinuria. Serum creatinine is an indirect measure of renal function. 3 It suffers from several limitations, including sizeable day-to-day variation within individuals. Measuring serum creatinine is easy and practical for frequent use, however, unlike some of the more direct methods of measuring GFR, which rely on clearance of isotopes or contrast materials. Serum creatinine rises along an exponential curve as GFR falls linearly. This has two important clinical implications. First, patients with significant renal function loss may have a serum creatinine in the normal range, as quoted by the laboratory. This is particularly likely in elderly or non-muscular individuals. Secondly, the absolute serum creatinine change for a given change in GFR becomes greater as renal function declines. For example, a change from 100 mmol/l to 150 mmol/l in serum creatinine implies a similar decline in GFR, as a rise from 400 mmol/l to 600 mmol/l. The easiest way to avoid these interpretive The Canadian Journal of CME / April
4 problems is to estimate the creatinine clearance from the serum creatinine using a formula (Figure 1). The one devised by Cockroft and Gault in the 1970s has stood the test of time and offers simplicity at the expense of accuracy in comparison to some newer versions. 4,5 Creatinine clearance is a reasonable approximation of GFR until renal function reaches low levels creatinine clearance progressively overestimates renal function as it declines due to tubular secretion of creatinine. 3 Similarly, urea clearance underestimates GFR because of its tubular re-absorption. The average of the 24-hour urea and creatinine clearances can be a useful approximation Because of overlapping risk factors and pathogenetic mechanisms in cardiovascular disease and renal disease, the same approaches can be useful in slowing the loss of renal function and preventing cardiovascular diseases and death. of GFR for those with advanced disease. Once the presence of chronic renal disease has been recognized, a search for the cause should follow. This includes a careful history of the timing of renal function loss, a check of medications, a family history and a clinical screen for systemic diseases. A standard urinalysis and renal imaging by ultrasound would be indicated in most cases. Involvement of a nephrologist may be useful in clarifying the diagnosis in some cases. The Progressive Nature of Renal Failure Established renal disease may progress even if the original cause is removed. Renal hemodynamics, growth factor and cytokine release, protein traffic through glomeruli and tubules, inflammatory mediators and tubular hypoxia may all contribute to this progression. The rate of loss of renal function varies, making individual prognostication challenging. About two-thirds of the normal elderly lose renal function at an average of about 1% per year. Patients with essential hypertension may lose renal function more quickly sometimes as much as 4% per year. About 5% of hypertensives with elevated creatinine will progress to a stage that requires dialysis. The rate of loss of renal function among those treated for a variety of chronic renal diseases averages 4% per annum. 6 However, poorly managed diabetic nephropathy and some glomerulonephritides may be associated with a 10% to 20% loss of renal function in a year. With these conditions, the rate of loss of renal function is strongly associated with the degree of proteinuria. 7 Those with persistent proteinuria of more than 3 g/day may progress to ESRD within two years. 7,8 Along with the specific renal diagnosis, in patients with chronic renal disease, one of the most consistent and best predictors of the rate of loss of renal function is the degree and persistence of proteinuria. 9 Several so-called cardiac risk factors are also associated with more rapid renal function loss. Higher blood pressure, especially systolic, is a potent risk factor for rapid renal function loss. 7,10,11 Smoking and higher blood lipids also contribute to rapid renal function loss. Ethnicity (the rate is slower in Caucasians than Blacks) and other genetic factors may influence the rate and risk of progression. A progressive loss of renal function is recognized by serial assessment of GFR. To achieve this, serial measurement of serum creatinine is mandatory, bearing in mind the caveats about interpretation mentioned above. 128 The Canadian Journal of CME / April 2001
5 Managing Chronic ACE inhibitors are widely thought to offer reno-protection beyond blood pressure lowering in both non-diabetics with chronic renal failure and diabetics. Because of the frequent co-existence of cardiovascular disease with renal disease, the extent of vascular disease should be determined. Renal failure is associated with an increase in vascular events and death. Even creatinine values of 130 mmol/l to 150 mmol/l increase death rates by three-fold within eight years. Cardiovascular death is 25 times as common as renal death in Type 2 diabetics with microalbuminuria. Because of their overlapping risk factors and pathogenetic mechanisms, the same approaches can be useful in slowing the loss of renal function and preventing cardiovascular diseases and death. Lowering blood pressure is the key to slowing many renal diseases. Angiotensin-converting enzyme (ACE) inhibition, dietary protein restriction, lipid management and avoidance of further renal insults (such as the use of nephrotoxins) also may be helpful. Tight glucose control in both Type 1 and 2 diabetes has been associated with the prevention and improvement of early-stage microvascular complications, including nephropathy. 12,13 The impact seems to be sustainable over several years, however, glucose control has little impact on the progression of advanced diabetic nephropathy. Lowering blood pressure reduces cardiovascular events and deaths, as well as slows the decline in renal function in diabetics The optimal blood pressure target is still controversial. Diabetics randomized to a diastolic target of less than 80 mmhg in the Hypertension Optimal Treatment (HOT) study had fewer cardiovascular events and deaths. 15 These results were mirrored by the Appropriate Blood Pressure Control n Diabetes (ABCD) trial, in which hypertensive Type 2 diabetics with a target diastolic pressure of less than 75 mmhg had fewer deaths than those targeted to between 80 mmhg to 89 mmhg diastolic. 16 Both of these pressure levels, however, had the same impact on renal function. As with diabetics, lowering blood pressure slows the loss of renal function in many other chronic renal diseases. The gain from lowering blood pressure is greater in those with heavier proteinuria. 10,11 Some authorities recommend titrating anti-hypertensives to minimize proteinuria and not just blood pressure. This is consistent with what we know of the pathogenesis and role of proteinuria, but there is no direct evidence documenting the efficacy of this approach. Based largely on The Canadian Journal of CME / April
6 Hypertension Cardiovascular disease Diabetes mellitus Unexplained anemia Family history of renal disease Abnormal urinalysis Screen for protein/microalbuminuria Serum creatinine Urinalysis Identify Risk of Progression Changing serum creatinine Degree of proteinuria Blood pressure Smoking history Management Check for cardiovascular disease Control blood pressure Consider ACE inhibition? Dietary protein restriction Lipid management Avoid further renal insults Consider nephrology consult Figure 2. Identification and management of chronic renal disease. the Modification of Diet in (MDRD) study, 10,11 guidelines recommend target blood pressures of less than 125/75 for patients with chronic renal failure and proteinuria of more than 1 g/day. 17 The safety of aiming for such pressures has been documented. It should be noted that it nearly always requires several anti-hypertensives in combination, including a diuretic, to achieve these targets. 15 ACE inhibitors are widely thought to offer renoprotection beyond blood pressure lowering in both non-diabetics with chronic renal failure 18 and dia- 132 The Canadian Journal of CME / April 2001
7 betics. 19,20 In comparison with placebo, ACE inhibition also slowed the decline in GFR over six years in normotensive Type 2 diabetics without microalbuminuria. 21 In such placebo trials, it is difficult to be sure that the benefit is not just due to blood pressure lowering. Nevertheless, follow-up of patients with proteinuria and chronic renal failure suggests long-term ACE inhibition, as part of the anti-hypertensive regimen, can be associated with the stabilization, and even improvement, of renal function. Given that combination therapy will be required to control blood pressure in most cases, the inclusion of an ACE inhibitor seems warranted, particularly given possible vasculoprotective effects. The role of low-protein diets in slowing renal function loss has been controversial. There is a potential for malnutrition. Dietary instruction and maintaining compliance requires major effort. The negative results of a large trial, the MDRD study, 10 dampened enthusiasm for this approach in many quarters. Nevertheless, recent meta-analyses suggest that lowering protein intake may provide a minor degree of benefit in slowing the decline in kidney function in both non-diabetics with chronic renal disease and Type 1 diabetics. However, the optimal dietary protein intake is not clear. For now, it is reasonable to aim for a protein intake of 0.6 g/kg of body weight/day to 0.8 g/kg of body weight/day. This intervention requires considerable input from a dietitian to be sustained, and mandates careful monitoring for protein malnutrition. A variety of studies link lipid abnormalities with a more rapid loss of renal function. The specific lipid parameters associated with risk have not been consistent. Currently, there are no data to show that treating lipid abnormalities slows the decline in renal function. Nevertheless, an active control of lipids is advised, given the burden of vascular disease associated with renal failure and the clear cardiovascular benefits of lowering lowdensity lipoprotein (LDL) and raising high-density lipoprotein (HDL) cholesterol in other populations at high risk. It requires considerable effort to carry out all of the above interventions. In addition, there is a need to monitor the progress of the renal failure serially. Frequent patient reviews are important to achieving goals and reinforcing therapeutic advice. It is unlikely that any one professional will have the time or resources to carry out all the required work for any number of patients with chronic renal disease. With this in mind, there has been a trend in recent years to develop specialized, multidisciplinary clinics to work in concert with primary-care providers and other care providers. It remains to be seen whether such concerted efforts can have an impact on the burden of ESRD. Conclusions Risk factors and treatment strategies for patients with kidney and cardiovascular disease overlap. Thus, evaluating renal function in patients with diabetes, hypertension and cardiovascular disease is essential. This should be done with urinalysis and serum creatinine as an estimate of GFR. The overall goal is to slow the progression of kidney disease and, ultimately, to decrease the associated morbidity and mortality. Strict control of blood pressure, ACE inhibitor use, dietary protein restriction and lipid management all have defined roles in achieving these goals. This approach is summarized in Figure 2. CME References 1. Mendelssohn DC, Barrett BJ, Brownscombe LM: Elevated levels of serum creatinine: Recommendations for management and referral. Can Med Assoc J 1999; 161: Meltzer S, Leiter L, Daneman D, et al: 1998 clinical practice guidelines for the management of diabetes in Canada. Can Med Assoc J 1998; 159 (Suppl. 8):S1-S Levey AS, Perrone RD, Madias NE: Serum creatinine and renal function. Ann Rev Med 1988; 39: The Canadian Journal of CME / April
8 4. Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: Levey AS, Bosch JP, Lewis JB, et al, for the Modification of Diet in Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: Hunsicker LG, Adler S, Caggiula A, et al: Predictors of the progression of renal disease in the Modification of Diet in Study. Kidney Int 1997; 51: Ruggenenti P, Gambara V, Perna A, et al: The nephropathy of non-insulin dependent diabetes: Predictors of outcome relative to diverse patterns of renal injury. J Am Soc Nephrol 1998; 9: The GISEN group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: Hunsicker LG, Adler S, Caggiula A, et al, for the Modification of Diet in Study Group: Predictors of the progression of renal disease in the Modification of Diet in Study. Kidney Int 1997; 51: Klahr S, Levey AS, Beck GJ, et al, for the Modification of Diet in Study Group: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. New Engl J Med 1994; 330: Peterson JC, Adler S, Burkart IM, et al: Blood pressure control, proteinuria and the progression of renal insufficiency. Kidney Int 1992; 42: The Diabetes Control and Complications Trial Research Group: The effect of intensive therapy of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): UK Prospective Diabetes Study (UKPDS) Group: Tight Prevacid is indicated for short-term treatment of reflux esophagitis and maintenance therapy of healed reflux esophagitis. Most common side effects ( > 3%) in short-term studies are headache and diarrhea. Doses higher than 30 mg per day should not be administered to patients with impaired hepatic function and the elderly. *After the first day of therapy, significantly more patients (p < 0.05) on Prevacid 30 mg (n = 402) compared to omeprazole 20 mg (n = 418) reported no daytime heartburn (48.7% vs. 37.6%) and nighttime heartburn (62% vs. 52%) in an 8-week randomized, double-blind study in patients with endoscopically diagnosed reflux esophagitis. 1 Consult Product Monograph for dosage recommendations. Abbott Laboratories, Limited Saint-Laurent, Québec H4S 1Z1 Product Monograph available on request.
9 blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: Hansson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group: Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: Estacio RO, Gifford N, Jeffers BW, et al: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23(Suppl. 2):B54-B Feldman RD, Campbell N, Larochelle P, et al: 1999 Canadian recommendations for the management of hypertension. Can Med Assoc J 1999; 161(Suppl. 12):S Giatras I, Lau J, Levey AS, for the Angiotensin- Converting-Enzyme Inhibition and Progressive Renal Disease Study Group: Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Ann Intern Med 1997; 127: Lewis EJ, Hunsicker LG, Bain RP, et al, for the Collaborative Study Group: The effect of angiotensinconverting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: Ravid M, Lang R, Rachmani R, et al: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: A 7- year follow-up study. Arch Intern Med 1996; 156: Ravid M, Brosh D, Levi Z, et al: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with Type 2 diabetes mellitus. Ann Intern Med 1998; 128:982-8.
Renal Protection Staying on Target
Update Staying on Target James Barton, MD, FRCPC As presented at the University of Saskatchewan's Management of Diabetes & Its Complications (May 2004) Gwen s case Gwen, 49, asks you to take on her primary
More informationKidney Disease. Chronic kidney disease (CKD) requiring dialysis. The F.P. s Role in the Management of Chronic. Stages
Focus on CME at McMaster University The F.P. s Role in the Management of Chronic Kidney Disease By David N. Churchill, MD, FRCPC, FACP Presented at McMaster University CME Half-Day in Nephrology for Family
More informationACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence?
Reviews ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence? George L. Bakris, MD; 1 and Matthew Weir, MD 2 Although angiotensin-converting
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationElevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC
Elevation of Serum Creatinine: When to Screen, When to Refer Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Presented at the University of Calgary s CME and Professional Development 2006-2007
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More information(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)
[1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationAssessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation
Nephrol Dial Transplant (2002) 17: 1909 1913 Original Article Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new () prediction equation
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationSpecial Challenges and Co-Morbidities
Special Challenges and Co-Morbidities Renal Disease/ Hypertension/ Diabetes in African-Americans M. Keith Rawlings, MD Medical Director Peabody Health Center AIDS Arms, Inc Dallas, TX Chair, Internal Medicine
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationThe relation between elevated blood pressure (BP) and
ACE Inhibitors and Appearance of Renal Events in Hypertensive Nephrosclerosis Julián Segura, Carlos Campo, José L. Rodicio, Luis M. Ruilope Abstract Nephrosclerosis constitutes a major cause of end-stage
More informationThe hypertensive kidney and its Management
The hypertensive kidney and its Management Dr H0 Chung Ping Hypertension Management Seminar 20061124 Hypertensive kidney Kidney damage asymptomatic till late stage Viscous cycle to augment renal damage
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationChronic Kidney Disease: Optimal and Coordinated Management
Chronic Kidney Disease: Optimal and Coordinated Management Michael Copland, MD, FRCPC Presented at University of British Columbia s 42nd Annual Post Graduate Review in Family Medicine Conference, Vancouver,
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationIntroduction to Clinical Diagnosis Nephrology
Introduction to Clinical Diagnosis Nephrology I. David Weiner, M.D. C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University of Florida College
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationThe Seventh Report of the Joint National Commission
The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationCharacteristics of factor x so that its clearance = GFR. Such factors that meet these criteria. Renal Tests. Renal Tests
Renal Tests Holly Kramer MD MPH Associate Professor of Public Health Sciences and Medicine Division of Nephrology and Hypertension Loyola University of Chicago Stritch School of Medicine Renal Tests 1.
More informationDiabetes has become the most common
P O S I T I O N S T A T E M E N T Diabetic Nephropathy AMERICAN DIABETES ASSOCIATION Diabetes has become the most common single cause of end-stage renal disease (ESRD) in the U.S. and Europe; this is due
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationDiabetes has become the most common
P O S I T I O N S T A T E M E N T Diabetic Nephropathy AMERICAN DIABETES ASSOCIATION Diabetes has become the most common single cause of end-stage renal disease (ESRD) in the U.S. and Europe; this is due
More informationCLINICIAN INTERVIEW A REVIEW OF THE CURRENT TREATMENT MODALITIES FOR DIABETIC NEPHROPATHY. Interview with Ralph Rabkin, MD
A REVIEW OF THE CURRENT TREATMENT MODALITIES FOR DIABETIC NEPHROPATHY Interview with Ralph Rabkin, MD Dr Rabkin is Professor of Medicine, Emeritus, Active, at Stanford University School of Medicine, Stanford,
More informationAcknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD
A Practical Approach to Chronic Kidney Disease Management for the Primary Care Practioner: A web-site sponsored by the National Kidney Foundation of Connecticut Robert Reilly, M.D. Acknowledgements National
More informationIrish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
More informationHypertension is an important global public
IN THE LITERATURE Blood Pressure Target in Individuals Without Diabetes: What Is the Evidence? Commentary on Verdecchia P, Staessen JA, Angeli F, et al; on behalf of the Cardio-Sis Investigators. Usual
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More information6/10/2014. Chronic Kidney Disease - General management and standard of care. Management of CKD according to stage (KDOQI 2002)
Chronic Kidney Disease - General management and standard of care Dr Nathalie Demoulin, Prof Michel Jadoul Cliniques universitaires Saint-Luc Université Catholique de Louvain What should and can be done
More informationQuality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care
Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationMANAGERIAL. Potential Application of the National Kidney Foundation s Chronic Kidney Disease Guidelines in a Managed Care Setting
Potential Application of the National Kidney Foundation s Chronic Kidney Disease Guidelines in a Managed Care Setting Micah L. Thorp, DO, MPH; and Loris Eastman, RN, CNN Chronic kidney disease (CKD) is
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES
Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of
More informationThe estimation of kidney function with different formulas in overall population
137 G E R I A T R I A 213; 7: 137-141 Akademia Medycyny ARTYKUŁ ORYGINALNY/ORIGINAL PAPER Otrzymano/Submitted: 28.8.213 Zaakceptowano/Accepted: 2.9.213 The estimation of kidney function with different
More informationManagement of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. Robert D. Toto, MD
R e v i e w P a p e r Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers Robert D. Toto, MD Both the prevalence and incidence of end-stage renal disease have been increasing
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationScreening for chronic kidney disease racial implications. Not everybody that pees has healthy kidneys!
Screening for chronic kidney disease racial implications Not everybody that pees has healthy kidneys! Screening for chronic kidney disease racial implications 1) Definition of CKD 2) Why should we screen
More informationOutline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationChronic kidney disease-what can you do and when to refer?
Chronic kidney disease-what can you do and when to refer? Dr Goh Heong Keong www.passpaces.com/kidney.htm Outline of Lecture Introduction Epidemiology of CKD in Malaysia/ World Complications of CKD What
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationManagement of Early Kidney Disease: What to do Before Referring to the Nephrologist
Management of Early Kidney Disease: What to do Before Referring to the Nephrologist Andrew S. Narva, MD, NIDDK Saturday, February 18, 2017 8:45 a.m. 9:30 a.m. Although evidence-based guidelines for managing
More informationRETARDING PROGRESSION OF CHRONIC KIDNEY DISEASE (CKD)
13 : 6 RETARDING PROGRESSION OF CHRONIC KIDNEY DISEASE (CKD) Abstract: Chronic Kidney Disease (CKD) is common, harmful and treatable. It is worldwide public health problem, with several adverse outcomes;
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationHot Topics in Diabetic Kidney Disease a primary care perspective
Hot Topics in Diabetic Kidney Disease a primary care perspective DR SARAH DAVIES GP PARTNER WITH SPECIAL INTEREST IN DIABETES, CARDIFF DUK CLINICAL CHAMPION NB MEDICAL HOT TOPICS PRESENTER AND DIABETES
More informationChronic Kidney Disease. Dr Mohan B. Biyani A. Professor of Medicine University of Ottawa/Ottawa Hospital
Chronic Kidney Disease Dr Mohan B. Biyani A. Professor of Medicine University of Ottawa/Ottawa Hospital Health Seminar Series Date 12 May 2013 Objectives Normal functioning of Kidneys. Risk factors to
More informationLab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.
Patient Education Lab Values Explained Common Tests to Help Diagnose Kidney Disease Lab work, urine samples and other tests may be given as you undergo diagnosis and treatment for renal failure. The test
More informationVA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERENCE CARDS Chronic Kidney Disease
VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERECE CARDS Chronic Kidney Disease CKD VA/DoD Clinical Practice Guideline for the Management
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Antihypertensive therapy in diabetic nephropathy GUIDELINES
Antihypertensive therapy in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Adequate control of blood pressure (BP) slows progression
More informationPreventing kidney failure: Primary care physicians must intervene earlier
REVIEW CME CREDIT CHRISTOPHER J. HEBERT, MD Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio Preventing kidney failure: Primary care physicians must intervene earlier ABSTRACT Mild chronic kidney
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationFrom Department of Medicine, David Geffen School of Medicine at UCLA.
FROM ISHIB 2009 THE PROS AND CONS OF STAGING CHRONIC KIDNEY DISEASE Background and Objectives: In 2002 the National Kidney Foundation Kidney Disease Outcomes Quality Initiative presented a new definition
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More informationRemission and Regression of Diabetic Nephropathy
515 Review Remission and Regression of Diabetic Nephropathy Hirofumi MAKINO, Yoshio NAKAMURA, and Jun WADA Diabetic nephropathy has become the single largest cause of end-stage renal disease (ESRD) worldwide.
More informationUniversity of Groningen. Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste
University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationInflammation in Renal Disease
Inflammation in Renal Disease Donald G. Vidt, MD Inflammation is a component of the major modifiable risk factors in renal disease. Elevated high-sensitivity C-reactive protein (hs-crp) levels have been
More informationLong-term outcomes in nondiabetic chronic kidney disease
original article http://www.kidney-international.org & 28 International Society of Nephrology Long-term outcomes in nondiabetic chronic kidney disease V Menon 1, X Wang 2, MJ Sarnak 1, LH Hunsicker 3,
More informationTread Carefully Because you Tread on my Nephrons. Prescribing Hints in Renal Disease
Tread Carefully Because you Tread on my Nephrons Prescribing Hints in Renal Disease David WP Lappin,, MB PhD FRCPI Clinical Lecturer in Medicine and Consultant Nephrologist and General Physician, Merlin
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationRenal Function and Associated Laboratory Tests
Renal Function and Associated Laboratory Tests Contents Glomerular Filtration Rate (GFR)... 2 Cockroft-Gault Calculation of Creatinine Clearance... 3 Blood Urea Nitrogen (BUN) to Serum Creatinine (SCr)
More informationPrevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study
International Journal of Advances in Medicine Sathyan S et al. Int J Adv Med. 2017 Feb;4(1):247-251 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20170120
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationCase Studies: Renal and Urologic Impairments Workshop
Case Studies: Renal and Urologic Impairments Workshop Justine Lee, MD, DBIM New York Life Insurance Co. Gina Guzman, MD, DBIM, FALU, ALMI Munich Re AAIM Triennial October, 2012 The Company You Keep 1 Case
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationOutline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationEducational and behavioral interventions hitherto published
Treatment of High-Risk Patients with Diabetes: Motivation and Teaching Intervention: A Randomized, Prospective 8-Year Follow-Up Study Rita Rachmani, Inna Slavacheski, Maya Berla, Ronni Frommer-Shapira,
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of steroid therapy GUIDELINES
Specific management of IgA nephropathy: role of steroid therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Steroid therapy may protect against progressive
More informationManagement of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA
Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and
More informationIdentifying and Managing Chronic Kidney Disease: A Practical Approach
Identifying and Managing Chronic Kidney Disease: A Practical Approach S. Neil Finkle, MD, FRCPC Associate Professor Division of Nephrology, Department of Medicine, Dalhousie University Program Director,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of fish oil
Specific management of IgA nephropathy: role of fish oil Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Early and prolonged treatment with fish oil may retard
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationChronic Kidney Disease. Basics of CKD Terms Diagnosis Management
Chronic Kidney Disease Basics of CKD Terms Diagnosis Management Review the prevalence of chronic kidney disease (CKD) Review how CKD develops Review populations at risk for CKD Review CKD diagnosis Objectives
More informationOffice Management of Reduced GFR Practical advice for the management of CKD
Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE
More informationCLINICAL PRACTICE. Clinical Practice. N Engl J Med, Vol. 347, No. 19 November 7,
Clinical Practice This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines,
More informationDiabetic Nephropathy
Diabetic Nephropathy Objectives: Know what Diabetic Nephropathy means. Know how common is Diabetic nephropathy in Saudi Arabia and to appreciate how bad are this complications. Know the risk factors of
More informationSwindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus
Swindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus 1 Contents Executive Summary... 3 How to Screen for Diabetic Nephropathy... 4 What to Measure... 4 Frequency
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationOut of date SUGGESTIONS FOR CLINICAL CARE (Suggestions are based on level III and IV evidence)
Membranous nephropathy role of cyclosporine therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. The use of cyclosporine therapy alone to prevent progressive
More informationDIABETES MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: DIABETES MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DIABETES MEASURES GROUP: #1. Diabetes: Hemoglobin A1c Poor Control #2. Diabetes: Low Density Lipoprotein (LDL-C)
More informationTHE KIDNEY AND SLE LUPUS NEPHRITIS
THE KIDNEY AND SLE LUPUS NEPHRITIS JACK WATERMAN DO FACOI 2013 NEPHROLOGY SIR RICHARD BRIGHT TERMINOLOGY RENAL INSUFFICIENCY CKD (CHRONIC KIDNEY DISEASE) ESRD (ENDSTAGE RENAL DISEASE) GLOMERULONEPHRITIS
More informationIs the new Mayo Clinic Quadratic (MCQ) equation useful for the estimation of glomerular filtration rate in type 2 diabetic patients?
Diabetes Care Publish Ahead of Print, published online October 3, 2008 The MCQ equation in DM2 patients Is the new Mayo Clinic Quadratic (MCQ) equation useful for the estimation of glomerular filtration
More informationRESEARCH. Population based screening for chronic kidney disease: cost effectiveness study
Population based screening for chronic kidney disease: cost effectiveness study Braden Manns, associate professor of medicine, 1,2,3,4 Brenda Hemmelgarn,associateprofessorofmedicine, 1,2,3,4 Marcello Tonelli,
More informationAddressing Chronic Kidney Disease in People with Multiple Chronic Conditions
Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions Andrew S Narva, MD Na/onal Kidney Disease Educa/on Program U.S. Department of Health and Human Services National Institute of
More informationKey Elements in Managing Diabetes
Key Elements in Managing Diabetes Presentor Disclosure No conflicts of interest to disclose Presented by Susan Cotey, RN, CDE Lennon Diabetes Center Stephanie Tubbs Jones Health Center Cleveland Clinic
More informationCase Study in Chronic Renal Failure
Case Study in Chronic Renal Failure Development of Knowledge Base: There were over 14,500 articles dealing with chronic renal failure entered into PubMed during 2000 2004. A current concept in this array
More informationRENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2
Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic
More information